2.4.0.8 Html 401 321 1 false 89 0 false 6 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.opexatherapeutics.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information true false R2.htm 103 - Statement - Consolidated Balance Sheets Sheet http://www.opexatherapeutics.com/taxonomy/role/StatementOfFinancialPositionClassified Consolidated Balance Sheets false false R3.htm 104 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.opexatherapeutics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Consolidated Balance Sheets (Parenthetical) false false R4.htm 105 - Statement - Consolidated Statements of Operations Sheet http://www.opexatherapeutics.com/taxonomy/role/StatementOfIncomeAlternative Consolidated Statements of Operations false false R5.htm 106 - Statement - Consolidated Statements of Changes In Stockholders' Equity Sheet http://www.opexatherapeutics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome Consolidated Statements of Changes In Stockholders' Equity false false R6.htm 107 - Statement - Consolidated Statements of Changes In Stockholders' Equity (Parenthetical) Sheet http://www.opexatherapeutics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical Consolidated Statements of Changes In Stockholders' Equity (Parenthetical) false false R7.htm 108 - Statement - Consolidated Statements of Cash Flows Sheet http://www.opexatherapeutics.com/taxonomy/role/StatementOfCashFlowsIndirect Consolidated Statements of Cash Flows false false R8.htm 109 - Disclosure - BUSINESS OVERVIEW AND SUMMARY OF ACCOUNTING POLICIES Sheet http://www.opexatherapeutics.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndAccountingPoliciesTextBlock BUSINESS OVERVIEW AND SUMMARY OF ACCOUNTING POLICIES false false R9.htm 110 - Disclosure - CASH AND CASH EQUIVALENTS Sheet http://www.opexatherapeutics.com/taxonomy/role/NotesToFinancialStatementsCashAndCashEquivalentsDisclosureTextBlock CASH AND CASH EQUIVALENTS false false R10.htm 111 - Disclosure - OTHER CURRENT ASSETS Sheet http://www.opexatherapeutics.com/taxonomy/role/NotesToFinancialStatementsOtherAssetsDisclosureTextBlock OTHER CURRENT ASSETS false false R11.htm 112 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://www.opexatherapeutics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock PROPERTY AND EQUIPMENT false false R12.htm 113 - Disclosure - DEFERRED FINANCING COSTS Sheet http://www.opexatherapeutics.com/taxonomy/role/NotesToFinancialStatementsDeferredChargesDisclosureTextBlock DEFERRED FINANCING COSTS false false R13.htm 114 - Disclosure - OTHER LONG TERM ASSETS Sheet http://www.opexatherapeutics.com/taxonomy/role/NotesToFinancialStatementsOtherNonCurrentAssetsTextBlock OTHER LONG TERM ASSETS false false R14.htm 115 - Disclosure - DEFERRED REVENUE Sheet http://www.opexatherapeutics.com/taxonomy/role/NotesToFinancialStatementsDeferredRevenueDisclosureTextBlock DEFERRED REVENUE false false R15.htm 116 - Disclosure - INCOME TAXES Sheet http://www.opexatherapeutics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock INCOME TAXES false false R16.htm 117 - Disclosure - CONVERTIBLE PROMISSORY NOTES Notes http://www.opexatherapeutics.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock CONVERTIBLE PROMISSORY NOTES false false R17.htm 118 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.opexatherapeutics.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock RELATED PARTY TRANSACTIONS false false R18.htm 119 - Disclosure - FAIR VALUE OF DERIVATIVE FINANCIAL INSTRUMENTS Sheet http://www.opexatherapeutics.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock FAIR VALUE OF DERIVATIVE FINANCIAL INSTRUMENTS false false R19.htm 120 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.opexatherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock COMMITMENTS AND CONTINGENCIES false false R20.htm 121 - Disclosure - SIGNIFICANT CONTRACTUAL SERVICE AND MILESTONE AGREEMENTS Sheet http://www.opexatherapeutics.com/taxonomy/role/NotesToFinancialStatementsBusinessAndContractualArrangementsDisclosureTextBlock SIGNIFICANT CONTRACTUAL SERVICE AND MILESTONE AGREEMENTS false false R21.htm 122 - Disclosure - EQUITY Sheet http://www.opexatherapeutics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock EQUITY false false R22.htm 123 - Disclosure - OPTIONS AND WARRANTS Sheet http://www.opexatherapeutics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock OPTIONS AND WARRANTS false false R23.htm 124 - Disclosure - LICENSES AND GAIN ON EXTINGUISHMENT OF DEBT Sheet http://www.opexatherapeutics.com/taxonomy/role/NotesToFinancialStatementsSignificantAgreementsDisclosureTextBlock LICENSES AND GAIN ON EXTINGUISHMENT OF DEBT false false R24.htm 125 - Disclosure - BUSINESS OVERVIEW AND SUMMARY OF ACCOUNTING POLICIES (Policies) Sheet http://www.opexatherapeutics.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndAccountingPoliciesTextBlockPolicies BUSINESS OVERVIEW AND SUMMARY OF ACCOUNTING POLICIES (Policies) false false R25.htm 126 - Disclosure - OTHER CURRENT ASSETS (Tables) Sheet http://www.opexatherapeutics.com/taxonomy/role/NotesToFinancialStatementsOtherAssetsDisclosureTextBlockTables OTHER CURRENT ASSETS (Tables) false false R26.htm 127 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://www.opexatherapeutics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables PROPERTY AND EQUIPMENT (Tables) false false R27.htm 128 - Disclosure - RELATED PARTY TRANSACTIONS (Tables) Sheet http://www.opexatherapeutics.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables RELATED PARTY TRANSACTIONS (Tables) false false R28.htm 129 - Disclosure - FAIR VALUE OF DERIVATIVE FINANCIAL INSTRUMENTS (Tables) Sheet http://www.opexatherapeutics.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables FAIR VALUE OF DERIVATIVE FINANCIAL INSTRUMENTS (Tables) false false R29.htm 130 - Disclosure - OPTIONS AND WARRANTS (Tables) Sheet http://www.opexatherapeutics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables OPTIONS AND WARRANTS (Tables) false false R30.htm 131 - Disclosure - Business Overview and Summary of Accounting Policies - Additional Information (Detail) Sheet http://www.opexatherapeutics.com/taxonomy/role/DisclosureBusinessOverviewAndSummaryOfAccountingPoliciesAdditionalInformation Business Overview and Summary of Accounting Policies - Additional Information (Detail) false false R31.htm 132 - Disclosure - Cash and Cash Equivalents - Additional Information (Detail) Sheet http://www.opexatherapeutics.com/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformation Cash and Cash Equivalents - Additional Information (Detail) false false R32.htm 133 - Disclosure - Other Current Assets (Detail) Sheet http://www.opexatherapeutics.com/taxonomy/role/DisclosureOtherCurrentAssets Other Current Assets (Detail) false false R33.htm 134 - Disclosure - Other Current Assets - Additional Information (Detail) Sheet http://www.opexatherapeutics.com/taxonomy/role/DisclosureOtherCurrentAssetsAdditionalInformation Other Current Assets - Additional Information (Detail) false false R34.htm 135 - Disclosure - Property and Equipment (Detail) Sheet http://www.opexatherapeutics.com/taxonomy/role/DisclosurePropertyAndEquipment Property and Equipment (Detail) false false R35.htm 136 - Disclosure - Property and Equipment - Additional Information (Detail) Sheet http://www.opexatherapeutics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation Property and Equipment - Additional Information (Detail) false false R36.htm 137 - Disclosure - Deferred Financing Costs - Additional Information (Detail) Sheet http://www.opexatherapeutics.com/taxonomy/role/DisclosureDeferredFinancingCostsAdditionalInformation Deferred Financing Costs - Additional Information (Detail) false false R37.htm 138 - Disclosure - Other Long Term Assets - Additional Information (Detail) Sheet http://www.opexatherapeutics.com/taxonomy/role/DisclosureOtherLongTermAssetsAdditionalInformation Other Long Term Assets - Additional Information (Detail) false false R38.htm 139 - Disclosure - Deferred Revenue - Additional Information (Detail) Sheet http://www.opexatherapeutics.com/taxonomy/role/DisclosureDeferredRevenueAdditionalInformation Deferred Revenue - Additional Information (Detail) false false R39.htm 140 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.opexatherapeutics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation Income Taxes - Additional Information (Detail) false false R40.htm 141 - Disclosure - Convertible Promissory Notes - Additional Information (Detail) Notes http://www.opexatherapeutics.com/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformation Convertible Promissory Notes - Additional Information (Detail) false false R41.htm 142 - Disclosure - Summary of Changes in Convertible Debt Third Parties Net of Unamortized Discount (Detail) Sheet http://www.opexatherapeutics.com/taxonomy/role/DisclosureSummaryOfChangesInConvertibleDebtThirdPartiesNetOfUnamortizedDiscount Summary of Changes in Convertible Debt Third Parties Net of Unamortized Discount (Detail) false false R42.htm 143 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://www.opexatherapeutics.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation Related Party Transactions - Additional Information (Detail) false false R43.htm 144 - Disclosure - Summary of Changes in Convertible Debt Related Parties Net of Unamortized Discount (Detail) Sheet http://www.opexatherapeutics.com/taxonomy/role/DisclosureSummaryOfChangesInConvertibleDebtRelatedPartiesNetOfUnamortizedDiscount Summary of Changes in Convertible Debt Related Parties Net of Unamortized Discount (Detail) false false R44.htm 145 - Disclosure - Fair Value of Derivatives Financial Instruments - Additional Information (Detail) Sheet http://www.opexatherapeutics.com/taxonomy/role/DisclosureFairValueOfDerivativesFinancialInstrumentsAdditionalInformation Fair Value of Derivatives Financial Instruments - Additional Information (Detail) false false R45.htm 146 - Disclosure - Changes in Fair Value of Derivative Financial Instruments Measured at Fair Value on Recurring Basis using Significant Unobservable Inputs (Detail) Sheet http://www.opexatherapeutics.com/taxonomy/role/DisclosureChangesInFairValueOfDerivativeFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisUsingSignificantUnobservableInputs Changes in Fair Value of Derivative Financial Instruments Measured at Fair Value on Recurring Basis using Significant Unobservable Inputs (Detail) false false R46.htm 147 - Disclosure - Variables used in Lattice Option Pricing Model for Derivative Liabilities (Detail) Sheet http://www.opexatherapeutics.com/taxonomy/role/DisclosureVariablesUsedInLatticeOptionPricingModelForDerivativeLiabilities Variables used in Lattice Option Pricing Model for Derivative Liabilities (Detail) false false R47.htm 148 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.opexatherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation Commitments and Contingencies - Additional Information (Detail) false false R48.htm 149 - Disclosure - Significant Contractual Service and Milestone Agreements - Additional Information (Detail) Sheet http://www.opexatherapeutics.com/taxonomy/role/DisclosureSignificantContractualServiceAndMilestoneAgreementsAdditionalInformation Significant Contractual Service and Milestone Agreements - Additional Information (Detail) false false R49.htm 150 - Disclosure - Equity - Additional Information (Detail) Sheet http://www.opexatherapeutics.com/taxonomy/role/DisclosureEquityAdditionalInformation Equity - Additional Information (Detail) false false R50.htm 151 - Disclosure - Options and Warrants - Additional Information (Detail) Sheet http://www.opexatherapeutics.com/taxonomy/role/DisclosureOptionsAndWarrantsAdditionalInformation Options and Warrants - Additional Information (Detail) false false R51.htm 152 - Disclosure - Summary Information Regarding Options and Warrants (Detail) Sheet http://www.opexatherapeutics.com/taxonomy/role/DisclosureSummaryInformationRegardingOptionsAndWarrants Summary Information Regarding Options and Warrants (Detail) false false R52.htm 153 - Disclosure - Summary of Options Outstanding and Exercisable (Detail) Sheet http://www.opexatherapeutics.com/taxonomy/role/DisclosureSummaryOfOptionsOutstandingAndExercisable Summary of Options Outstanding and Exercisable (Detail) false false R53.htm 154 - Disclosure - Summary of Warrant Outstanding and Exercisable (Detail) Sheet http://www.opexatherapeutics.com/taxonomy/role/DisclosureSummaryOfWarrantOutstandingAndExercisable Summary of Warrant Outstanding and Exercisable (Detail) false false R54.htm 155 - Disclosure - Licenses and Gain on Extinguishment of Debt - Additional Information (Detail) Sheet http://www.opexatherapeutics.com/taxonomy/role/DisclosureLicensesAndGainOnExtinguishmentOfDebtAdditionalInformation Licenses and Gain on Extinguishment of Debt - Additional Information (Detail) false false All Reports Book All Reports Element us-gaap_CommonStockSharesOutstanding had a mix of decimals attribute values: -5 0. Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate had a mix of decimals attribute values: 2 4. Warning: The equity rendering routine was not applied to 106 - Statement - Consolidated Statements of Changes In Stockholders' Equity. None of the elements feature the 'periodStartLabel' preferred label role. 'Shares' elements on report '131 - Disclosure - Business Overview and Summary of Accounting Policies - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '131 - Disclosure - Business Overview and Summary of Accounting Policies - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '132 - Disclosure - Cash and Cash Equivalents - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '134 - Disclosure - Other Current Assets - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '138 - Disclosure - Other Long Term Assets - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '140 - Disclosure - Income Taxes - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '150 - Disclosure - Equity - Additional Information (Detail)' had a mix of different decimal attribute values. Process Flow-Through: 103 - Statement - Consolidated Balance Sheets Process Flow-Through: Removing column 'Sep. 24, 2013' Process Flow-Through: Removing column 'Jan. 31, 2013' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: Removing column 'Dec. 31, 2009' Process Flow-Through: Removing column 'Dec. 31, 2008' Process Flow-Through: Removing column 'Dec. 31, 2007' Process Flow-Through: Removing column 'Dec. 31, 2006' Process Flow-Through: Removing column 'Dec. 31, 2005' Process Flow-Through: Removing column 'Dec. 31, 2004' Process Flow-Through: Removing column 'Dec. 31, 2003' Process Flow-Through: 104 - Statement - Consolidated Balance Sheets (Parenthetical) Process Flow-Through: Removing column 'Sep. 24, 2013' Process Flow-Through: Removing column 'Dec. 14, 2012' Process Flow-Through: 105 - Statement - Consolidated Statements of Operations Process Flow-Through: Removing column '1 Months Ended Sep. 24, 2013' Process Flow-Through: Removing column '11 Months Ended Dec. 31, 2003' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2011' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2010' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2009' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2008' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2007' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2006' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2005' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2004' Process Flow-Through: 106 - Statement - Consolidated Statements of Changes In Stockholders' Equity Process Flow-Through: Removing column '1 Months Ended Dec. 23, 2013' Process Flow-Through: Removing column '1 Months Ended Sep. 30, 2013' Process Flow-Through: Removing column '1 Months Ended Sep. 24, 2013' Process Flow-Through: Removing column '131 Months Ended Dec. 31, 2013' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2005 Licensing Agreements' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2004 Licensing Agreements' Process Flow-Through: Removing column '24 Months Ended Jan. 31, 2005 Licensing Agreements' Process Flow-Through: Removing column '1 Months Ended Jul. 01, 2013 Accrued Interest' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2013 Accrued Interest' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2012 Accrued Interest' Process Flow-Through: Removing column '1 Months Ended Feb. 28, 2013 Common Stock' Process Flow-Through: 107 - Statement - Consolidated Statements of Changes In Stockholders' Equity (Parenthetical) Process Flow-Through: 108 - Statement - Consolidated Statements of Cash Flows opxa-20131231.xml opxa-20131231.xsd opxa-20131231_cal.xml opxa-20131231_def.xml opxa-20131231_lab.xml opxa-20131231_pre.xml true true